This batch of results is excellent, my favourite parts:
1. Keytruda and Cavatak seem to be getting good results in metastatic bladder cancer and non small cell lung cancer (I am sure this one is the big value driver for VLA)
2. The mouse results are outstanding for Cavatak - combinations are consistently better with Cavatak than without.
Will be very interesting to see what Mr Market makes of the new results!
VLA Price at posting:
81.0¢ Sentiment: Hold Disclosure: Held
